The COVID-19 pandemic disrupted South Africa's health systems and product supply in 2020. Firstline treatment regimens of TEE (tenofovir/ emtricitabine/ efavirenz) and TLD (tenofovir/ lamivudine /dolutegravir) were particularly impacted. Through careful management of suppliers and active stock monitoring under the Affordable Medicine Directorate (AMD) leadership, there are no further supply constraints anticipated in the short to mid-term. The table below highlights healthy stock and pipeline levels, especially for TLD. TLD stock levels can therefore support an increased transition rate across all provinces TLD remains the preferred treatment for first-line patients, as in the current guidelines; hence, the National Department of Health (NDoH) continues to advocate for a continuous transition to this highly potent regimen which is a crucial step for improving viral suppression and reaching 90-90-90 targets.